Trial reportBlood2019
Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.
Trial report in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02631746 (Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma), which is not on this map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Who cites it
69 citing papers in PubMed, 105 citations in OpenAlex.
- Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.Signal transduction and targeted therapy · 2024Trial
- Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment.JCI insight · 2023Trial
- Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.Journal for immunotherapy of cancer · 2022Trial
- Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.Journal for immunotherapy of cancer · 2022Trial
- Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL.Blood advances · 2021Trial
- Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia.Blood advances · 2020Trial
- Host genetic determinants of HTLV-1 infection outcomes.Immunologic research · 2026Review
- T cell lymphomas: cancers of aberrant immune synapse signalling.Nature reviews. Immunology · 2026Review
- Article
- Revealing tumor microenvironmental heterogeneity and prognostic value in angioimmunoblastic T-cell lymphoma via spatial transcriptome sequencing.Cell death & disease · 2026Article
- Valproate reactivates HTLV-1 tax and reduces ABCB1/MDR1 expression in PBMCs derived from ATLL patients.Frontiers in oncology · 2026Article
- Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.Journal of personalized medicine · 2025Review
- Article
- Molecular mechanisms of viral oncogenesis in haematological malignancies: perspectives from metabolic reprogramming, epigenetic regulation and immune microenvironment remodeling.Experimental hematology & oncology · 2025Review
- Beyond monotherapy: multimodal strategies integrating immune checkpoint inhibitors in lymphoma management.Frontiers in immunology · 2025Review
- In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma.Journal of experimental & clinical cancer research : CR · 2024Article
- Development of Subcutaneous Panniculitis-Like T-cell Lymphoma After Immune Checkpoint Inhibitor Treatment.Cureus · 2024Article
- Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.Haematologica · 2023Article
- Review
- Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review.Biomolecules · 2023Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
Abstract
Immune checkpoint inhibitors are a powerful new tool in the treatment of cancer, with prolonged responses in multiple diseases, including hematologic malignancies, such as Hodgkin lymphoma. However, in a recent report, we demonstrated that the PD-1 inhibitor nivolumab led to rapid progression in patients with adult T-cell leukemia/lymphoma (ATLL) (NCT02631746). We obtained primary cells from these patients to determine the cause of this hyperprogression. Analyses of clonality, somatic mutations, and gene expression in the malignant cells confirmed the report of rapid clonal expansion after PD-1 blockade in these patients, revealed a previously unappreciated origin of these malignant cells, identified a novel connection between ATLL cells and tumor-resident regulatory T cells (Tregs), and exposed a tumor-suppressive role for PD-1 in ATLL. Identifying the mechanisms driving this alarming outcome in nivolumab-treated ATLL may be broadly informative for the growing problem of rapid progression with immune checkpoint therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.